1. Generics Bulletin
  2. >>Products

Alteogen Eyes Partnerships And 2025 Approval For EU Eylea Biosimilar

Korean Firm Files After Biocon Received First And Only European Aflibercept Approval

 
• By Dean Rudge

Korean firm Alteogen has disclosed its plans for its proposed biosimilar to Eylea following a landmark acceptance of the company’s filing by the European Medicines Agency.

European flags (Markus Pfaff/Shutterstock.com)
• Source: Shutterstock

Alteogen’s Altos Biologics says it intends to negotiate license agreements with “potential distributors worldwide,” in the wake of filing its ALT-L9 proposed biosimilar to Eylea (aflibercept) with the European Medicines Agency.

The Korean firm is allied on development of its aflibercept biosimilar with Japan’s Kissei Pharmaceutical

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.